Baidu
map

Ocul Surf:睑板腺功能障碍诊断与治疗的新策略

2017-03-27 luowenbo MedSci原创

睑板腺功能障碍(MGD)是一种常见的慢性病,会极大地降低患者的生活质量。睑板腺主要为泪膜提供脂质,能抑制泪液的蒸发从而保持眼表湿润,因此MGD是导致蒸发性干眼病(DED)的原因之一,同时发现,在原发性水缺乏性DED时也能检测到MGD.

睑板腺功能障碍诊断与治疗的新策略

睑板腺功能障碍(MGD)是一种常见的慢性病,会极大地降低患者的生活质量。睑板腺主要为泪膜提供脂质,能抑制泪液的蒸发从而保持眼表湿润,因此MGD是导致蒸发性干眼病(DED)的原因之一,同时发现,在原发性水缺乏性DED时也能检测到MGD.

阻塞性MGD是目前最常见的MGD类型,也是该研究的重点。MGD可能是几种单独致病条件(原发阻塞性睑板腺角化过度、睑板腺分泌异常、眼睑炎、角膜炎症和损伤、微生物菌群改变、DED等)的互和作用所致,另外,皮肤病如酒糟鼻也是MGD病理进程中的一种重要促进因素。

精确地诊断MGD仍然非常具有挑战性,因为很难区分MGD与眼表疾病,但是MGD的精确诊断是其用药治疗的关键。近年来飞速发展的眼成像技术为更好地了解眼部疾病提供了很好的技术手段。

本文介绍一种优化的通过目前可用的MGD检测方法与试验可以更精确诊断MGD的方法,同时还探讨了MGD的治疗方法和眼科疾病的新型技术的使用与发展,如:活体激光共聚焦显像技术。

原文出处:


本文系梅斯医学(MedSci)原创编译,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1719043, encodeId=76f21e190430f, content=<a href='/topic/show?id=e32e915e89c' target=_blank style='color:#2F92EE;'>#诊断与治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91578, encryptionId=e32e915e89c, topicName=诊断与治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85a832689492, createdName=木头人524, createdTime=Thu Aug 31 19:43:00 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421068, encodeId=25f81421068ce, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Wed Mar 29 13:43:00 CST 2017, time=2017-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478387, encodeId=438c14e838701, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Wed Mar 29 13:43:00 CST 2017, time=2017-03-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1719043, encodeId=76f21e190430f, content=<a href='/topic/show?id=e32e915e89c' target=_blank style='color:#2F92EE;'>#诊断与治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91578, encryptionId=e32e915e89c, topicName=诊断与治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85a832689492, createdName=木头人524, createdTime=Thu Aug 31 19:43:00 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421068, encodeId=25f81421068ce, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Wed Mar 29 13:43:00 CST 2017, time=2017-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478387, encodeId=438c14e838701, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Wed Mar 29 13:43:00 CST 2017, time=2017-03-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1719043, encodeId=76f21e190430f, content=<a href='/topic/show?id=e32e915e89c' target=_blank style='color:#2F92EE;'>#诊断与治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91578, encryptionId=e32e915e89c, topicName=诊断与治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85a832689492, createdName=木头人524, createdTime=Thu Aug 31 19:43:00 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421068, encodeId=25f81421068ce, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Wed Mar 29 13:43:00 CST 2017, time=2017-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478387, encodeId=438c14e838701, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Wed Mar 29 13:43:00 CST 2017, time=2017-03-29, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map